Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1781174 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $1.52Day +6.29%Mkt cap $61M1Y +15.2%Off 52W high −57.3%Vol (1Y) 93.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 925 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest3.5% of sh out |
| Days to cover2.3d |
| 13F net flow (QoQ)−0.31% |
| Top-10 13F concentration93.0% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$77.3M |
| ROE−53.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−36.9% |
| 1Y+15.2% |
| 3Y−87.8% |
| Since incept. (ann.)−47.6% |
Total return through 2026-07-30 · series begins 2022-11-15. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)93.6% |
| Ann. volatility (3Y)104.1% |
| Sharpe (1Y)0.61 |
| Sharpe (3Y)−0.16 |
| Max drawdown (1Y)−57.1% |
| Max drawdown (3Y)−91.6% |
| Beta (3Y vs SPY)2.05 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 8.3M | $12M | 21.53% | +0.0% |
| Sands Capital Alternatives, LLC | 2.1M | $3M | 5.48% | +0.0% |
| WELLINGTON MANAGEMENT GROUP LLP | 888,130 | $1M | 2.29% | +0.0% |
| ACADIAN ASSET MANAGEMENT LLC | 845,973 | $1M | 2.18% | +45.6% |
| RENAISSANCE TECHNOLOGIES LLC | 758,440 | $1M | 1.96% | +19.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 722,035 | $1M | 1.86% | new |
| MARSHALL WACE, LLP | 560,436 | $779,007 | 1.45% | +13.0% |
| TWO SIGMA INVESTMENTS, LP | 389,395 | $541,259 | 1.01% | −33.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$0.49 | — | — | — |
| 2025-09-30 | 2025-11-13 | −$0.47 | — | — | — |
| 2025-06-30 | 2025-08-13 | −$0.55 | — | — | — |
| 2025-03-31 | 2025-05-14 | −$0.51 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
